Verkazia Now Available for Vernal Keratoconjunctivitis
Verkazia is an oil-in-water cationic emulsion that works by inhibiting T-cell activation and reducing the level of immune cells and mediators.
Ocular Allergy/Inflammation
Erectile Dysfunction Meds Tied to Higher Risk for Vision Issues
Regular users may be at risk for serous retinal detachment, retinal vascular occlusion, and ischemic optic neuropathy
Lastacaft Eye Drops Now Available Over-the-Counter
In December 2021, the FDA approved the prescription to OTC switch for Lastacaft.
FDA Approves Disposable Contacts With Antihistamine for Allergic Conjunctivitis
Acuvue Theravision with Ketotifen reduced ocular itching within 3 minutes and the response was sustained for up to 12 hours after lens insertion.
Dextenza Approved for Ocular Itching Associated With Allergic Conjunctivitis
The approval was based on data from three phase 3 studies that evaluated the efficacy and safety of Dextenza in patients with allergic conjunctivitis.
FDA Approves Generic Version of Durezol
Difluprednate Ophthalmic Emulsion 0.05% is an AB-rated generic equivalent of Durezol.
Verkazia Approved for Vernal Keratoconjunctivitis
The approval was based on data from two randomized, multicenter, double-masked, vehicle-controlled trials that evaluated the efficacy and safety of Verkazia in patients with VKC.
Pataday Once Daily Relief Extra Strength Available Over-the-Counter
Pataday Once Daily Relief Extra Strength is indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander.
Eysuvis Now Available For Dry Eye Disease
Eysuvis (loteprednol etabonate ophthalmic suspension) is now available for the short-term treatment of the signs and symptoms of dry eye disease.
Eysuvis Approved for Dry Eye Disease
Results from 4 clinical trials showed that treatment with Eysuvis was associated with significant improvements in both the signs and symptoms of dry eye disease.
